Tesaro wins FDA OK for an IV ver­sion of chemo drug, launch­es dis­cov­ery deal with Evotec

→ The FDA has ap­proved an IV ver­sion of the al­ready OK’d drug Varu­bi, used to treat the nau­sea and vom­it­ing trig­gered by chemother­a­py. “The ma­jor­i­ty of NK-1 re­cep­tor an­tag­o­nist dos­es are ad­min­is­tered in­tra­venous­ly in the U.S., and with the in­tro­duc­tion of Varu­bi IV, we now of­fer health­care providers a unique, easy-to-use op­tion that fits well in­to stan­dard op­er­at­ing prac­tices of a chemother­a­py clin­ic or hos­pi­tal,” said Tesaro pres­i­dent Mary Lynne Hed­ley.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER